Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 29:13:906586.
doi: 10.3389/fendo.2022.906586. eCollection 2022.

Emerging Roles of the Atypical Chemokine Receptor 3 (ACKR3) in Cardiovascular Diseases

Affiliations
Review

Emerging Roles of the Atypical Chemokine Receptor 3 (ACKR3) in Cardiovascular Diseases

Vincent Duval et al. Front Endocrinol (Lausanne). .

Abstract

Chemokines, and their receptors play a crucial role in the pathophysiology of cardiovascular diseases (CVD). Chemokines classically mediate their effects by binding to G-protein-coupled receptors. The discovery that chemokines can also bind to atypical chemokine receptors (ACKRs) and initiate alternative signaling pathways has changed the paradigm regarding chemokine-related functions. Among these ACKRs, several studies have highlighted the exclusive role of ACKR3, previously known as C-X-C chemokine receptor type 7 (CXCR7), in CVD. Indeed, ACKR3 exert atheroprotective, cardioprotective and anti-thrombotic effects through a wide range of cells including endothelial cells, platelets, inflammatory cells, fibroblasts, vascular smooth muscle cells and cardiomyocytes. ACKR3 functions as a scavenger receptor notably for the pleiotropic chemokine CXCL12, but also as a activator of different pathways such as β-arrestin-mediated signaling or modulator of CXCR4 signaling through the formation of ACKR3-CXCR4 heterodimers. Hence, a better understanding of the precise roles of ACKR3 may pave the way towards the development of novel and improved therapeutic strategies for CVD. Here, we summarize the structural determinant characteristic of ACKR3, the molecules targeting this receptor and signaling pathways modulated by ACKR3. Finally, we present and discuss recent findings regarding the role of ACKR3 in CVD.

Keywords: ACKR3; atypical chemokine receptors; cardiovascular diseases; chemokine; signalling.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of signaling pathways for ACKR3. Chemokines ligands CXCL12 and CXCL11 can induce phosphorylation of ACKR3 by GRK or others kinases, the recruitment of β-arrestins and trigger intracellular G-protein independent signaling. ACKR3 is also able to scavenge various ligands (CXCL12, CXCL11, ADM, PAMP, PAMP12, opioїd peptides) at the cell surface, internalized these ligands which subsequently result in degradation in lysosome while the receptor recycles to the cell membrame. ACKR3 is also able to interact with G-proteins without to lead to their activation. However, in two specific cellular types, primary rodent astrocytes and human glioma cells, ACKR3 can be coupled to Gα-protein and triggers PLC and MAPK activation. GRK, G-protein receptor kinase; ADM, adrenomedullin; PAMP, proadrenomedullinN-terminal 20 peptide; PLC, phospholipase C; MAPK, mitogen-activated protein kinase. (Figure created with BioRender.com).
Figure 2
Figure 2
Role of ACKR3 in the infarcted heart. ACKR3 expression is increased in several cells of the heart following myocardial infarction, and can play multiple roles after activation by endogenous and exogenous ligands. ACKR3 exerts cardioprotective effects by acting either as a rheostat for certain ligands through scavenging activity or as a co-partner through dimerization with other receptors. In addition, ACKR3 may trigger activation of β-arrestin-dependent pathways. (Figure created with BioRender.com).

References

    1. Back M, Weber C, Lutgens E. Regulation of Atherosclerotic Plaque Inflammation. J Intern Med (2015) 278:462–82. - PubMed
    1. Michel JB, Martin-Ventura JL, Nicoletti A, Ho-Tin-Noe B. Pathology of Human Plaque Vulnerability: Mechanisms and Consequences of Intraplaque Haemorrhages. Atherosclerosis (2014) 234:311–9. - PubMed
    1. Hansson GK, Libby P, Tabas I. Inflammation and Plaque Vulnerability. J Intern Med (2015) 278:483–93. - PMC - PubMed
    1. Aifah A, Iwelunmor J, Akwanalo C, Allison J, Amberbir A, Asante KP, et al. . The Kathmandu Declaration on Global CVD/Hypertension Research and Implementation Science: A Framework to Advance Implementation Research for Cardiovascular and Other Noncommunicable Diseases in Low- and Middle-Income Countries. Glob Heart (2019) 14:103–7. - PMC - PubMed
    1. Gencer S, van der Vorst EPC, Aslani M, Weber C, Doring Y, Duchene J. Atypical Chemokine Receptors in Cardiovascular Disease. Thromb Haemost (2019) 119:534–41. - PubMed

Publication types

MeSH terms

LinkOut - more resources